Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2008 financial results after the NASDAQ Global Market closes on Tuesday, August 5, 2008. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the second quarter 2008 financial results and to provide a corporate update.

The conference call may be accessed by dialing 877.419.6590 for domestic callers and 719.325.4872 for international callers. Please specify to the operator that you would like to join the "Arena Second Quarter Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independentl
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
(Date:8/26/2015)... , August 26, 2015 ... factors fueling the optimism in biotech,s forecast is ... and life sciences advancements.  Active biotechnology & healthcare ... BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) ...
(Date:8/25/2015)... 2015   WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... Kong Exchange Stock Code: 0950), a research-based biopharmaceutical company ... 20 years of operations in China ... an agreement whereby WuXi,s Laboratory Testing Division (LTD) will ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... FOLD ) today announced that it will host an ... PM at the Four Seasons Hotel in New,York City. The ... 2 clinical trials performed for Amigal(TM) (migalastat hydrochloride),for Fabry disease ... and development programs at the company., A live audio ...
... (Pre-Market Notification), Pathway for AppyScore(TM), the First Blood-based Screening and Triage ... ... 27 AspenBio Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical ... and humans, has,received an official response from the Food and Drug ...
... Israel, Nov. 27 Shamir,Optical Industry Ltd. (Nasdaq: ... technology to the progressive ophthalmic lens,market, today announced unaudited ... For the quarter ended September 30, 2007, revenues ... for the third quarter of 2006.,Gross profit for the ...
Cached Biology Technology:Amicus Therapeutics to Host R&D Day 2Amicus Therapeutics to Host R&D Day 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 2Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 3Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 5Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 6Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 7Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 8Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 9Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 10
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... "Cognitive Assessment and Training Market by Assessment Type (Pen ... Classroom Learning, Brain Training, Corporate Learning, Academic Research), Vertical ... MarketsandMarkets, Cognitive Assessment and Training Market to grow from ... by 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... Network and University of Toronto have identified a small ... with chronic Hepatitis C will be able to respond ... the basis of a simple new test in the ... , The study, published in the May issue of ...
... new research tool will allow University of Oregon scientists ... their quest to test and understand the human body's ... environmental chamber, is a 12-foot-square room capable of simulating ... a set point between 14 and 122 degrees Fahrenheit, ...
... stem cells can develop in the laboratory into the early ... work opens up the possibility that eggs and sperm could ... therapeutic cloning and the creation of more stem cells for ... from a range of diseases. , Behrouz Aflatoonian will tell ...
Cached Biology News:Identification of specific genes predicts which patients will respond to Hepatitis C treatment 2Identification of specific genes predicts which patients will respond to Hepatitis C treatment 3Going To Extremes To Improve Human Health 2Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 2Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 3
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... Biotin label transfer is fast emerging ... interaction discovery and confirmation. Until now, only ... targeted with label transfer reagents such as ... chain analog, Mts-Atf-LC-Biotin, are exciting additions to ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
Biology Products: